Researchers have consistently identified olfactory dysfunction—the loss of smell—as an early and reliable marker of neurodegeneration, appearing years before cognitive decline or motor symptoms become apparent. This connection is not coincidental: the olfactory bulb, the brain structure that processes smell, is one of the first regions affected by the pathological changes underlying Alzheimer’s disease and Parkinson’s disease. In people with early-stage cognitive impairment, smell loss correlates with the accumulation of tau and amyloid proteins, the hallmarks of Alzheimer’s pathology, making olfactory testing a potential screening tool for neurodegeneration before symptoms become severe.
The biological mechanisms linking smell to brain health are increasingly well understood. The olfactory system is unique in that olfactory neurons have direct contact with the external environment and connect almost immediately to the brain without passing through protective barriers that shield other sensory pathways. This direct exposure means olfactory neurons are among the first neurons in the body to encounter pathogenic proteins, environmental toxins, and viral particles that may trigger or accelerate neurodegeneration.
Table of Contents
- How Smell Loss Signals Brain Disease
- Olfactory Loss in Parkinson’s Disease and Other Neurodegenerative Conditions
- Cellular Mechanisms: How Smell Neurons Degenerate
- Detecting Smell Loss: Clinical Tests and Implications
- Environmental and Genetic Risk Factors in Olfactory Degeneration
- The Olfactory Biomarker in Dementia Screening and Prevention Trials
- Clinical Implications for Early Detection and Monitoring
How Smell Loss Signals Brain Disease
The olfactory bulb undergoes changes in Alzheimer’s disease earlier than most other brain regions. Pathological examination of Alzheimer’s brains shows that amyloid-beta plaques and tau tangles accumulate in the olfactory bulb even in people with only mild cognitive impairment, suggesting that smell loss may precede noticeable memory problems by years. One study from Mayo Clinic researchers found that people with olfactory dysfunction scored significantly lower on cognitive tests than age-matched controls with normal smell, independent of other health factors.
The specificity of smell loss as a neurodegeneration marker is particularly striking because smell dysfunction in Alzheimer’s is different from age-related smell loss alone. People with Alzheimer’s show impaired odor identification and discrimination—they cannot recognize or name smells correctly—rather than simply having reduced sensitivity to odors. This qualitative difference suggests a fundamental problem with how the brain is processing olfactory information, not just how the nose is detecting it. A patient might detect the presence of coffee but be unable to identify it as coffee, a sign of central nervous system dysfunction rather than peripheral sensory impairment.
Olfactory Loss in Parkinson’s Disease and Other Neurodegenerative Conditions
Parkinson’s disease shows an even stronger connection to smell loss than Alzheimer’s disease. Approximately 90% of people with Parkinson’s experience olfactory dysfunction, and crucially, smell loss often appears 5 to 10 years before motor symptoms like tremor or rigidity emerge. This long preclinical period makes smell testing potentially valuable for identifying people at high risk for Parkinson’s before the disease becomes diagnosed. The University of Michigan’s study of cognitively normal older adults found that those with poor odor identification had double the risk of developing Parkinson’s disease over a 5-year follow-up period.
The pathological basis of smell loss in Parkinson’s involves alpha-synuclein accumulation in olfactory neurons and the olfactory bulb. Alpha-synuclein is the primary protein involved in Parkinson’s pathology, and it accumulates in the olfactory system decades before it appears in the substantia nigra, the brain region most visibly affected in Parkinson’s motor symptoms. This progression suggests that olfactory neurons may be a vulnerable entry point for pathological protein spreading through the nervous system. Other neurodegenerative conditions also associate with smell loss, including Lewy body dementia, frontotemporal dementia, and multiple system atrophy, though the strength of this association varies by disease. A limitation of using smell testing as a screening tool is that smell dysfunction is not specific to neurodegeneration alone—it occurs with normal aging, head injuries, chronic rhinosinusitis, and viral infections, meaning that a positive test requires careful clinical correlation rather than acting as a standalone diagnostic marker.
Cellular Mechanisms: How Smell Neurons Degenerate
The olfactory neurons undergo structural changes in neurodegenerative disease that reflect broader brain pathology. Olfactory bulb neurons accumulate the same abnormal proteins found throughout the brains of people with Alzheimer’s and Parkinson’s disease. These proteins—amyloid-beta, tau, and alpha-synuclein—spread along neural circuits, and the olfactory system appears to be positioned at the beginning of these spreading pathways. Researchers have proposed several mechanisms: pathogens or environmental toxins might enter the body through the olfactory epithelium in the nose and travel directly into the brain along olfactory nerve fibers, or the immune response to these foreign substances might trigger neuroinflammation that propagates throughout connected brain regions.
Mitochondrial dysfunction and oxidative stress also contribute to olfactory neuron degeneration. Olfactory neurons are metabolically active cells with high energy demands, and they appear particularly vulnerable to the mitochondrial impairment and free radical damage that occur in neurodegenerative disease. When researchers examine the olfactory bulbs of people with Alzheimer’s disease post-mortem, they consistently find evidence of oxidative stress, mitochondrial damage, and neuroinflammation alongside the protein aggregates. A practical consequence of this cellular understanding is that compounds targeting oxidative stress or protein aggregation show promise in olfactory system models, suggesting that the olfactory system might be a useful model for testing drugs before evaluating them in the broader brain.
Detecting Smell Loss: Clinical Tests and Implications
Odor identification testing, the most common clinical assessment, asks patients to smell and identify different odors from a standardized test kit. The University of Pennsylvania Smell Identification Test (UPSIT) and the Sniffin’ Sticks test are the most widely validated instruments. In research settings, these tests have proven remarkably good at differentiating people with preclinical Alzheimer’s disease from cognitively normal controls. A study published in *Neurology* found that among cognitively normal people with amyloid positron emission tomography (PET) scans showing brain amyloid accumulation, those with poor odor identification had significantly faster rates of cognitive decline over five years compared to those with preserved smell.
The advantage of smell testing as a screening method is its simplicity, low cost, and non-invasiveness compared to brain imaging or biomarker blood tests. A brief 40-item smell identification test takes about 10 minutes to administer in a clinical setting. The limitation, however, is that smell loss is not pathognomonic—not unique to neurodegeneration. Many conditions cause smell impairment, and normal aging itself causes gradual decline in smell function, meaning that a abnormal smell test must be interpreted alongside other clinical information rather than used in isolation.
Environmental and Genetic Risk Factors in Olfactory Degeneration
The pathways connecting smell loss to neurodegeneration reveal multiple potential entry points for risk factors. Viral infections affecting the olfactory epithelium have emerged as a concern; post-infectious olfactory dysfunction can persist long after the acute infection resolves, and the virus may directly access olfactory neurons. Some research suggests that severe coronavirus infections causing olfactory loss might increase neurodegeneration risk through direct viral damage to olfactory neurons or triggering excessive neuroinflammation, though long-term follow-up data remain incomplete. Occupational or environmental exposure to toxins may accelerate olfactory system damage in people already predisposed to neurodegeneration.
Agricultural exposure to pesticides, long-term exposure to air pollution, and exposure to industrial chemicals all associate with increased risk of Parkinson’s disease in epidemiological studies, and these exposures may partially exert their effects through olfactory system pathways. A warning for people working in agriculture or industrial settings with known neurotoxin exposure is that preserving nasal and respiratory health through protective equipment may have protective effects beyond immediate respiratory concerns. Genetic factors also influence olfactory vulnerability to disease. Apolipoprotein E4 (APOE4), a genetic risk factor for Alzheimer’s disease, associates with greater olfactory dysfunction in cognitively normal older adults, suggesting that genetic predisposition to Alzheimer’s pathology manifests through olfactory system degeneration before systemic cognitive decline appears.
The Olfactory Biomarker in Dementia Screening and Prevention Trials
Olfactory dysfunction is increasingly incorporated into research protocols as an objective measure of neurodegeneration burden. Prevention trials targeting cognitively normal older adults with biomarkers of Alzheimer’s pathology often include odor identification testing as an outcome measure, alongside cognitive testing and brain imaging.
The appeal is clear: smell testing provides non-invasive, repeated measurements without radiation exposure or the expense of positron emission tomography scans. Some prevention research programs now use smell testing in the initial screening phases to enrich populations likely to have underlying neurodegeneration. The Amyloid Biomarker Study, for example, uses olfactory function as one criterion for identifying cognitively normal participants who warrant further biomarker testing before enrollment in prevention trials.
Clinical Implications for Early Detection and Monitoring
For individuals concerned about cognitive health, particularly those with family history of dementia or Parkinson’s disease, smell testing offers an accessible screening tool that can be discussed with a primary care physician. The test itself carries no risk, involves no medication, and results can guide whether further neurological evaluation or biomarker testing is warranted. A person whose smell identification score falls substantially below the age-expected range might benefit from closer monitoring of cognitive function and consideration of brain biomarker testing.
Clinicians increasingly incorporate odor identification assessment into the cognitive evaluation of older adults, alongside standard cognitive screening tests. In research environments, olfactory testing has identified preclinical disease with sufficient accuracy that it is being evaluated as a potential component of population screening strategies. The progression from research finding to clinical practice remains incomplete, but major medical centers now offer smell testing as part of comprehensive dementia risk assessment, and the American Academy of Neurology recognizes olfactory dysfunction as a potential early marker of neurodegenerative disease.
- —
